留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

粪菌移植治疗炎症性肠病的争议

张发明 李玥

张发明, 李玥. 粪菌移植治疗炎症性肠病的争议[J]. 协和医学杂志, 2019, 10(3): 211-215. doi: 10.3969/j.issn.1674-9081.2019.03.005
引用本文: 张发明, 李玥. 粪菌移植治疗炎症性肠病的争议[J]. 协和医学杂志, 2019, 10(3): 211-215. doi: 10.3969/j.issn.1674-9081.2019.03.005
Fa-ming ZHANG, Yue LI. Controversy of Fecal Microbiota Transplantation in Treating Patients with Inflammatory Bowel Disease[J]. Medical Journal of Peking Union Medical College Hospital, 2019, 10(3): 211-215. doi: 10.3969/j.issn.1674-9081.2019.03.005
Citation: Fa-ming ZHANG, Yue LI. Controversy of Fecal Microbiota Transplantation in Treating Patients with Inflammatory Bowel Disease[J]. Medical Journal of Peking Union Medical College Hospital, 2019, 10(3): 211-215. doi: 10.3969/j.issn.1674-9081.2019.03.005

粪菌移植治疗炎症性肠病的争议

doi: 10.3969/j.issn.1674-9081.2019.03.005
基金项目: 

中国医学科学院医学与健康科技创新工程协同创新团队"人体微生物组平台建设与应用研究" 2017-I2M-3-017

江苏省重大研发计划 BE2018751

详细信息
    通讯作者:

    李玥 电话:010-69155751, E-mail:liyue@pumch.cn

  • 中图分类号: R459.9

Controversy of Fecal Microbiota Transplantation in Treating Patients with Inflammatory Bowel Disease

More Information
    Corresponding author: LI Yue Tel:86-10-69155751, E-mail: liyue@pumch.cn
  • 摘要: 已有报道表明粪菌移植治疗炎症性肠病前景可观, 且针对溃疡性结肠炎的临床随机对照研究支持粪菌移植的有效性。但涉及粪菌制备的方法学、移植途径、供体筛选、患者选择以及诱发病情活动的潜在风险等方面尚存诸多未知, 因此, 粪菌移植目前仅适合在临床试验等特定条件下用于炎症性肠病治疗。
    利益冲突  无
  • 图  1  基于智能粪菌分离系统的高级别净化实验室,仅用于从健康供体粪便中分离纯化菌群

  • [1] Paramsothy S, Kamm MA, Kaakoush NO, et al. Multidonor intensive faecal microbiota transplantation for active ulcerative colitis:a randomised placebo-controlled trial[J]. Lancet, 2017, 389:1218-1228. doi:  10.1016/S0140-6736(17)30182-4
    [2] Costello SP, Hughes PA, Waters O, et al. Effect of Fecal Microbiota Transplantation on 8-Week Remission in Patients With Ulcerative Colitis:A Randomized Clinical Trial[J]. JAMA, 2019, 321:156-164. doi:  10.1001/jama.2018.20046
    [3] Ding X, Li Q, Li P, et al. Efficacy, safety and long-term follow up of step-up fecal microbiota transplantation strategy in moderate to severe ulcerative colitis[J]. Drug Saf, 2019.doi: 10.1007/s40264-019-00809-2.[Epub ahead of print].
    [4] Wang H, Cui B, Li Q, et al. The safety of fecal microbiota transplantation for Crohn's disease:Findings from long-term study[J]. Adv Ther, 2018, 35:1935-1944. doi:  10.1007/s12325-018-0800-3
    [5] Qazi T, Amaratunga T, Barnes EL, et al. The risk of inflammatory bowel disease flares after fecal microbiota transplantation:systematic review and meta-analysis[J]. Gut Microbes, 2017, 8:574-588. doi:  10.1080/19490976.2017.1353848
    [6] Kump P, Wurm P, Grochenig HP, et al. The taxonomic composition of the donor intestinal microbiota is a major factor influencing the efficacy of faecal microbiota transplantation in therapy refractory ulcerative colitis. Aliment[J]. Pharmacol Ther, 2018, 47, 67-77. https://pubmed.ncbi.nlm.nih.gov/29052237/
    [7] Moayyedi P, Surette MG, Kim PT, et al. Fecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized controlled trial[J].Gastroenterology, 2015, 149:102-109. doi:  10.1053/j.gastro.2015.04.001
    [8] Rossen NG, Fuentes S, van der Spek MJ, et al. Findings from a randomized controlled trial of fecal transplantation for patients with ulcerative colitis[J]. Gastroenterology, 2015, 149:110-118. doi:  10.1053/j.gastro.2015.03.045
    [9] Fuentes S, Rossen NG, van der Spek MJ, et al. Microbial shifts and signatures of long-term remission in ulcerative colitis after faecal microbiota transplantation[J]. ISME J, 2017, 11:1877-1889. doi:  10.1038/ismej.2017.44
    [10] Zhang F, Cui B, He X, et al. FMT-standardization Study Group. Microbiota transplantation:concept, methodology and strategy for its modernization[J]. Protein Cell, 2018, 9:462-473. doi:  10.1007/s13238-018-0541-8
    [11] Wilson BC, Vatanen T, Cutfield WS, et al. The Super-Donor Phenomenon in Fecal Microbiota Transplantation[J]. Front Cell Infect Microbiol, 2019, 9:2. doi:  10.3389/fcimb.2019.00002
    [12] Costello SP, Conlon MA, Vuaran MS, et al. Faecal microbiota transplant for recurrent Clostridium difficile infection using long-term frozen stool is effective:clinical efficacy and bacterial viability data[J]. Aliment Pharmacol Ther, 2015, 42:1011-1018. doi:  10.1111/apt.13366
    [13] Staley C, Hamilton MJ, Vaughn BP, et al. Successful resolution of recurrent Clostridium difficile infection using freeze-dried, encapsulated fecal microbiota; pragmatic cohort study[J]. Am J Gastroenterol, 2017, 112:940-947. doi:  10.1038/ajg.2017.6
    [14] Kao D, Roach B, Silva M, et al. Effect of oral capsule-vs colonoscopy-delivered fecal microbiota transplantation on recurrent Clostridium difficile infection:a randomized clinical trial[J]. JAMA, 2017, 318:1985-1993. doi:  10.1001/jama.2017.17077
    [15] Uygun A, Ozturk K, Demirci H, et al. Fecal microbiota transplantation is a rescue treatment modality for refractory ulcerative colitis[J]. Medicine (Baltimore), 2017, 96:e6479. doi:  10.1097/MD.0000000000006479
    [16] Sood A, Mahajan R, Juyal G, et al. Efficacy of fecal microbiota therapy in steroid dependent ulcerative colitis:a real world intention-to-treat analysis[J]. Intest Res, 2019, 17:78-86. doi:  10.5217/ir.2018.00089
    [17] Li P, Zhang T, Xiao Y, et al. Timing for the second fecal microbiota transplantation to maintain the long-term benefit from the first treatment for Crohn's disease[J]. Appl Microbiol Biotechnol, 2019, 103:349-360. doi:  10.1007/s00253-018-9447-x
    [18] Singh S, Feuerstein JD, Binion DG, et al. AGA Technical Review on the Management of Mild-to-Moderate Ulcerative Colitis[J]. Gastroenterology, 2019, 156:769-808. doi:  10.1053/j.gastro.2018.12.008
    [19] Imdad A, Nicholson MR, Tanner-Smith EE, et al. Fecal transplantation for treatment of inflammatory bowel disease[J]. Cochrane Database Syst Rev, 2018, 11:CD012774. https://pubmed.ncbi.nlm.nih.gov/30480772/
  • 加载中
图(1)
计量
  • 文章访问数:  281
  • HTML全文浏览量:  83
  • PDF下载量:  28
  • 被引次数: 0
出版历程
  • 收稿日期:  2019-02-13
  • 刊出日期:  2020-09-18

目录

    /

    返回文章
    返回

    【温馨提醒】近日,《协和医学杂志》编辑部接到作者反映,有多名不法人员冒充期刊编辑发送见刊通知,鼓动作者添加微信,从而骗取版面费的行为。特提醒您,本刊与作者联系的方式均为邮件通知或电话,稿件进度通知邮箱为:mjpumch@126.com,编辑部电话为:010-69154261,请提高警惕,谨防上当受骗!如有任何疑问,请致电编辑部核实。谢谢!